vs
Side-by-side financial comparison of Aterian, Inc. (ATER) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $15.1M, roughly 1.5× Aterian, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -52.5%, a 59.7% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs -38.5%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -13.5%).
Aterian, Inc. is a technology-enabled consumer products company that leverages artificial intelligence and data analytics to identify market demand, develop, source and distribute a wide portfolio of affordable goods spanning home improvement, wellness, personal care, pet supplies and outdoor recreation. It primarily sells its products through leading global e-commerce platforms, with core markets covering North America and Europe.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
ATER vs CUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.1M | $21.9M |
| Net Profit | $-7.9M | $1.6M |
| Gross Margin | 56.1% | — |
| Operating Margin | -51.1% | 9.0% |
| Net Margin | -52.5% | 7.2% |
| Revenue YoY | -38.5% | 1292.3% |
| Net Profit YoY | -512.2% | 116.7% |
| EPS (diluted) | — | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.1M | $21.9M | ||
| Q3 25 | $19.0M | $2.1M | ||
| Q2 25 | $19.5M | $3.0M | ||
| Q1 25 | $15.4M | $421.0K | ||
| Q4 24 | $24.6M | $1.6M | ||
| Q3 24 | $26.2M | $3.3M | ||
| Q2 24 | $28.0M | $2.7M | ||
| Q1 24 | $20.2M | $1.7M |
| Q4 25 | $-7.9M | $1.6M | ||
| Q3 25 | $-2.3M | $-7.4M | ||
| Q2 25 | $-4.9M | $-8.5M | ||
| Q1 25 | $-3.9M | $-12.3M | ||
| Q4 24 | $-1.3M | — | ||
| Q3 24 | $-1.8M | $-8.7M | ||
| Q2 24 | $-3.6M | $-10.2M | ||
| Q1 24 | $-5.2M | $-12.3M |
| Q4 25 | 56.1% | — | ||
| Q3 25 | 56.1% | — | ||
| Q2 25 | 54.3% | — | ||
| Q1 25 | 61.4% | — | ||
| Q4 24 | 63.4% | — | ||
| Q3 24 | 60.3% | — | ||
| Q2 24 | 60.4% | — | ||
| Q1 24 | 65.1% | — |
| Q4 25 | -51.1% | 9.0% | ||
| Q3 25 | -10.7% | -353.4% | ||
| Q2 25 | -23.1% | -292.3% | ||
| Q1 25 | -24.1% | -2921.4% | ||
| Q4 24 | -6.5% | — | ||
| Q3 24 | -6.6% | -264.2% | ||
| Q2 24 | -11.5% | -390.6% | ||
| Q1 24 | -26.1% | -737.8% |
| Q4 25 | -52.5% | 7.2% | ||
| Q3 25 | -12.0% | -346.6% | ||
| Q2 25 | -25.0% | -287.1% | ||
| Q1 25 | -25.4% | -2911.4% | ||
| Q4 24 | -5.3% | — | ||
| Q3 24 | -6.8% | -259.6% | ||
| Q2 24 | -13.0% | -382.7% | ||
| Q1 24 | -25.5% | -719.1% |
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.17 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.17 | ||
| Q2 24 | — | $-0.20 | ||
| Q1 24 | — | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.9M | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.2M | $26.4M |
| Total Assets | $29.6M | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.9M | $27.1M | ||
| Q3 25 | $7.6M | $11.7M | ||
| Q2 25 | $10.5M | $27.5M | ||
| Q1 25 | $14.3M | $13.1M | ||
| Q4 24 | $18.0M | $22.5M | ||
| Q3 24 | $16.1M | $32.4M | ||
| Q2 24 | $20.3M | $30.0M | ||
| Q1 24 | $17.5M | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $15.2M | $26.4M | ||
| Q3 25 | $22.6M | $13.2M | ||
| Q2 25 | $24.3M | $18.2M | ||
| Q1 25 | $27.0M | $6.6M | ||
| Q4 24 | $30.0M | $17.5M | ||
| Q3 24 | $30.6M | $25.4M | ||
| Q2 24 | $30.9M | $21.6M | ||
| Q1 24 | $33.0M | $30.0M |
| Q4 25 | $29.6M | $42.2M | ||
| Q3 25 | $40.1M | $31.6M | ||
| Q2 25 | $45.4M | $40.7M | ||
| Q1 25 | $49.8M | $22.3M | ||
| Q4 24 | $49.5M | $32.2M | ||
| Q3 24 | $52.1M | $44.8M | ||
| Q2 24 | $59.9M | $42.3M | ||
| Q1 24 | $55.7M | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.0M | $-1.1M |
| Free Cash FlowOCF − Capex | $-1.0M | — |
| FCF MarginFCF / Revenue | -6.9% | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.0M | $-1.1M | ||
| Q3 25 | $-1.6M | $-9.0M | ||
| Q2 25 | $-4.4M | $-3.4M | ||
| Q1 25 | $-3.9M | $-8.2M | ||
| Q4 24 | $-9.0K | $-36.3M | ||
| Q3 24 | $-722.0K | $-7.5M | ||
| Q2 24 | $2.9M | $-10.0M | ||
| Q1 24 | $-6.0K | $-9.8M |
| Q4 25 | $-1.0M | — | ||
| Q3 25 | $-1.6M | — | ||
| Q2 25 | $-4.4M | $-3.4M | ||
| Q1 25 | — | $-8.3M | ||
| Q4 24 | — | $-36.4M | ||
| Q3 24 | — | $-7.5M | ||
| Q2 24 | $2.9M | $-10.0M | ||
| Q1 24 | $-42.0K | $-9.8M |
| Q4 25 | -6.9% | — | ||
| Q3 25 | -8.4% | — | ||
| Q2 25 | -22.7% | -116.5% | ||
| Q1 25 | — | -1976.7% | ||
| Q4 24 | — | -2309.3% | ||
| Q3 24 | — | -225.7% | ||
| Q2 24 | 10.3% | -376.2% | ||
| Q1 24 | -0.2% | -573.0% |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.2% | 0.0% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.0% | 35.6% | ||
| Q4 24 | 0.0% | 4.2% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 0.2% | 3.2% |
| Q4 25 | — | -0.68× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATER
| Sales Channel Directly To Consumer | $13.1M | 87% |
| Heating Cooling And Air Quality | $2.1M | 14% |
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
